Market Overview

Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy

Share:
Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy

SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals. 

It found further reason to celebrate Monday with the conversion of a new Street advocate.

The Rating

Morgan Stanley analyst Matthew Harrison initiated coverage on Sage with an Overweight rating and $225 price target.

The Thesis

Sage is developing a pipeline of GABA-receptor agents to treat central nervous system diseases with a mechanism that's potentially faster, more widely applicable and has fewer pronounced side effects than current standards of care.

Brexanolone, Sage’s treatment for postpartum depression to be submitted to the U.S. Food and Drug Administration in the first half of the year, is expected to post peak U.S. sales of $775 million, Harrison said in a Monday note. 

“Given the lack of standard treatment and the modest benefit available with generic antidepressants, we believe brexanolone can be a [nearly] $1 billion global drug,” the analyst said. 

That compounds Sage’s long-term opportunity in SAGE-217, which is seen to have potential in depression, bipolar disorder and insomnia.

“We see continued derisking of '217 driving SAGE higher,” the analysts wrote, forecasting more than $2.5 billion in peak sales.

Price Action

At the time of publication, shares were set to open up 1.4 percent at $166.50.

Related Links:

The Companies That Led 2017's Biotech Rally

Pharma M&A Picks Up Momentum

Latest Ratings for SAGE

DateFirmActionFromTo
May 2020RBC CapitalReiteratesOutperform
May 2020WedbushDowngradesOutperformNeutral
May 2020SunTrust Robinson HumphreyMaintainsHold

View More Analyst Ratings for SAGE
View the Latest Analyst Ratings

 

Related Articles (SAGE)

View Comments and Join the Discussion!

Posted-In: antidepressants BrexanoloneAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
GNMKCanaccord GenuityMaintains20.0
MCOUBSMaintains344.0
LIIUBSMaintains235.0
QDELPiper SandlerMaintains250.0
LOWBarclaysMaintains150.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com